文献速递乳腺妇产影像US

HER2阳性乳腺癌新辅助化疗疗效的超声影像组学早期预测

Early Prediction Of Treatment Response To Neoadjuvant Chemotherapy Based On Pre-treatment Ultrasound Radiomics of HER2-positive Breast Cancer Patients by Radiomics-based Model: A Dual-center Retrospective Study.
PubMed 文献 · Acad Radiol · 2026-08-18

本研究为双中心回顾性研究,纳入659例接受新辅助化疗的HER2阳性乳腺癌患者,基于治疗前超声影像组学特征构建预测病理完全缓解模型。整合临床危险因素与影像组学标签的联合模型在训练及内外验证队列中AUC均优于单纯临床或影像组学模型。

要点

  • 治疗前超声影像组学特征可早期预测HER2阳性乳腺癌新辅助化疗后病理完全缓解。
  • 联合临床因素的影像组学模型预测效能显著优于单纯临床或影像组学模型。
  • 双中心验证显示联合模型预测稳定性良好,可辅助临床治疗决策。

核心结论

  • 临床-影像组学联合模型对HER2阳性乳腺癌新辅助化疗后病理完全缓解的预测效能优于单纯影像组学模型和单纯临床模型。
  • 联合模型在内部验证队列和独立外部验证队列中均表现稳定。

研究设计与样本

  • 双中心回顾性研究,共纳入659例接受新辅助化疗的HER2阳性乳腺癌患者。
  • 训练队列283例,内部验证队列121例,来自中心1;独立外部验证队列255例,来自中心2。
  • 中心1入组时间为2015年1月至2023年12月,中心2为2018年1月至2024年12月。
  • 以手术病理标本作为评估病理完全缓解的金标准。
  • 影像组学特征通过冗余降维后,采用最小绝对收缩和选择算子回归进行特征筛选并构建影像组学标签。

诊断标准与关键数值

  • 临床模型在训练队列中预测病理完全缓解的AUC为0.699。
  • 影像组学标签模型在训练队列中预测病理完全缓解的AUC为0.817。
  • 整合临床风险因素与影像组学标签的联合模型在全部队列中AUC为0.861,经DeLong检验显著高于临床模型和影像组学模型。

临床应用与阅片要点

  • 治疗前超声影像组学分析可用于HER2阳性乳腺癌新辅助化疗疗效的早期无创预测。
  • 联合临床风险因素可进一步提升影像组学模型的预测准确性。
  • 该模型经双中心外部验证,提示具备潜在多中心临床应用推广价值。

局限性

  • 本研究为回顾性设计,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: To develop and validate a radiomics-based clinical model for the preoperative prediction of pathological complete response (pCR) to neoadjuvant chemotherapy (NACT) in human epidermal growth factor receptor 2 (HER2) -positive breast cancer patients.

MATERIALS AND METHODS: This retrospective study included HER2 -positive breast cancer patients who underwent preoperative NACT. Patients were recruited from Center 1 during the period January 2015 to December 2023, and from Center 2 during January 2018 to December 2024. When assessing pCR, surgical specimens served as the gold standard. The radiomics signature (RS) was first refined through redundancy and dimensionality reduction to mitigate overfitting. The retained features were then used to build a Least Absolute Shrinkage and Selection Operator (LASSO) regression model for further feature selection and RS optimization. Subsequently, an integrated model incorporating independent clinical risk factors and the RS was developed. Model performance was compared using the DeLong test on area under the curve (AUC) values.

RESULTS: A total of 659 patients were included, consisting of a training cohort (n=283) and an internal validation cohort (IVC) (n=121) from Center 1, and an independent external validation cohort (EVC) (n=255) from Center 2. The clinical model and RS model showed acceptable performance in predicting pCR, with AUC values of 0.699 and 0.817 respectively observed in the training cohort (TC). The integrated model demonstrated significantly higher predictive accuracy (AUC = 0.861) compared to both the clinical and RS models across all cohorts. The statistical significance of this difference was confirmed using DeLong's test.

CONCLUSION: The clinical-radiomics combined model demonstrates improved and stable predictive performance for early response to NACT compared with radiomics-only and clinical-only models in both internal and external validation cohorts.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Du, Zha, Pan, et al. Early Prediction Of Treatment Response To Neoadjuvant Chemotherapy Based On Pre-treatment Ultrasound Radiomics of HER2-positive Breast Cancer Patients by Radiomics-based Model: A Dual-center Retrospective Study. Acad Radiol. 2026. PMID: 42613278. doi:10.1016/j.acra.2026.07.062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。